Tritz, Z. P., Ayasoufi, K., Wolf, D. M., Owens, C. A., Malo, C. S., Himes, B. T., … Johnson, A. J. (2023). Supplementary Figure 1 from Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression. https://doi.org/10.1158/2326-6066.23283418.v1

Tritz, Zachariah P., Katayoun Ayasoufi, Delaney M. Wolf, Carley A. Owens, Courtney S. Malo, Benjamin T. Himes, Cori E. Fain, et al. “Supplementary Figure 1 from Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression,” June 2, 2023. https://doi.org/10.1158/2326-6066.23283418.v1.

Tritz ZP, Ayasoufi K, Wolf DM, Owens CA, Malo CS, Himes BT, et al. Supplementary Figure 1 from Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression. 2023.

Tritz, Zachariah P., et al. Supplementary Figure 1 from Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression. 2 June 2023. Crossref, doi:10.1158/2326-6066.23283418.v1.

Tritz ZP, Ayasoufi K, Wolf DM, Owens CA, Malo CS, Himes BT, Fain CE, Goddery EN, Yokanovich LT, Jin F, Hansen MJ, Parney IF, Wang C, Moynihan KD, Irvine DJ, Wittrup KD, Diaz Marcano RM, Vile RG, Johnson AJ. Supplementary Figure 1 from Anti–PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression. 2023.